Grifols (GRF) AI Stock Analysis

• Market Cap: €7.63B
• Dividend Yield: 1.2%
• Average Volume (3M): 2.02M
• Price to Earnings (P/E): 28.6
• Beta (1Y): 1.22
• Revenue Growth: 9.32%
• EPS Growth: 95.66%
• Country: ES
• Employees: 23,833
• Sector: Healthcare
• Sector Strength: 41
• Industry: Drug Manufacturers - General
• EPS (TTM): 0.17
• Shares Outstanding: 426,129,800
• 10 Day Avg. Volume: 1,444,490
• 30 Day Avg. Volume: 2,024,879
• PEG Ratio: 0.24
• Price to Book (P/B): 1.06
• Price to Sales (P/S): 0.86
• P/FCF Ratio: 9.29
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €13.25
• Price Target Upside: 5.49% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 4

• Rating: 58 Neutral
• Price Target: €14.00 ▲(11.46% Upside)

Grifols demonstrates solid financial performance with strong revenue growth and improved cash flow, but faces challenges with high leverage and a constrained net profit margin. The technical analysis indicates strong bullish momentum, though overbought signals suggest caution. Valuation metrics point to potential overvaluation.

Grifols Business Overview & Revenue Model

Company Description

Grifols (GRF) is a global healthcare company based in Spain, specializing in the development, production, and marketing of plasma-derived medicines. It operates primarily in the biopharmaceutical sector, focusing on therapies for rare and chronic diseases. Grifols' core products include immunoglobulins, albumin, and clotting factors derived from human plasma, which are essential for treating conditions such as immune deficiencies, hemophilia, and liver diseases. The company is also involved in the hospital and diagnostic sectors, providing a range of products and services that support healthcare professionals and patients.

How the Company Makes Money

Grifols generates revenue primarily through the sale of its plasma-derived therapies, which are essential for treating various medical conditions. The company has established a robust network of plasma collection centers, which ensure a steady supply of raw materials for its products. Key revenue streams include the sale of immunoglobulins, albumin, and clotting factors, as well as diagnostic products and services. Additionally, Grifols has formed significant partnerships with healthcare institutions and organizations, enhancing its market reach and contributing to its earnings. The company's commitment to research and development also allows it to innovate and expand its product offerings, thereby driving growth and profitability.

Grifols Financial Statement Overview

Summary

Grifols shows strong revenue growth and improved cash flow metrics. Profitability margins are healthy, but the net profit margin remains constrained. The balance sheet reflects high leverage, which may pose future financial risks, but current cash flow improvements provide a positive outlook.

Income Statement

Grifols has demonstrated strong revenue growth, with a 9.41% increase from 2023 to 2024. The gross profit margin has remained stable around 39-40%, and the EBIT and EBITDA margins showed improvement, indicating enhanced operational efficiency. However, the net profit margin is relatively low at 2.18% for 2024, reflecting pressure on net income despite revenue growth.

Balance Sheet

The company maintains a high debt-to-equity ratio of 1.72 in 2024, indicating significant leverage, which could pose financial risk. However, a moderate return on equity of 2.67% suggests the company is generating a modest return on its investments. The equity ratio of 27.49% indicates a balanced capital structure but highlights reliance on debt financing.

Cash Flow

Grifols' free cash flow improved significantly from negative in 2023 to positive in 2024, highlighting better cash management. The operating cash flow to net income ratio of 5.75 suggests strong cash generation relative to net income, indicating healthy cash flow capabilities. The free cash flow to net income ratio is 4.27, demonstrating efficient conversion of income into free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	7.45B	7.21B	6.59B	6.06B	4.93B	5.34B
Gross Profit	3.03B	2.85B	2.49B	2.23B	1.96B	2.26B
EBITDA	1.67B	1.61B	1.18B	1.16B	922.47M	1.37B
Net Income	297.45M	156.92M	59.31M	208.28M	265.33M	618.55M
Balance Sheet
Total Assets	19.77B	21.41B	21.44B	21.53B	19.23B	15.27B
Cash, Cash Equivalents and Short-Term Investments	565.80M	1.00B	645.72M	591.24M	2.68B	590.51M
Total Debt	8.82B	10.09B	10.12B	9.75B	9.32B	6.91B
Total Liabilities	12.17B	12.80B	13.47B	13.08B	11.09B	8.55B
Stockholders Equity	5.17B	5.88B	5.83B	6.13B	6.10B	5.11B
Cash Flow
Free Cash Flow	811.20M	669.63M	-87.14M	-386.43M	281.89M	747.78M
Operating Cash Flow	1.10B	902.17M	208.28M	-10.87M	596.98M	1.11B
Investing Cash Flow	-806.60M	886.67M	-397.64M	-1.98B	-29.39M	-858.12M
Financing Cash Flow	-1.77B	-1.36B	186.04M	-173.49M	1.47B	-354.40M

Grifols Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 12.56
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ES:GRF, the sentiment is Positive. The current price of 12.56 is above the 20-day moving average (MA) of 12.49, above the 50-day MA of 11.39, and above the 200-day MA of 9.70, indicating a bullish trend. The MACD of 0.36 indicates Positive momentum. The RSI at 56.91 is Neutral, neither overbought nor oversold. The STOCH value of 20.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ES:GRF.

Grifols Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ROVI	71 Outperform	€2.84B	21.59	25.44%	1.67%	-3.73%	-7.56%
FAE	68 Neutral	€1.32B	12.49	14.89%	4.25%	11.04%	8.29%
RJF	64 Neutral	€243.38M	36.70	3.04%	1.65%	0.58%	-30.60%
PHM	62 Neutral	$1.50B	34.84	21.61%	0.97%	19.18%	―
Sector *	62 Neutral	€1.85B	21.43	10.06%	2.09%	7.83%	13.92%
GRF	58 Neutral	€7.63B	28.56	5.53%	1.20%	9.32%	95.66%
ALM	53 Neutral	€2.41B	112.20	1.45%	1.42%	13.32%	―

Grifols Corporate Events

Grifols Exceeds Q1 2025 Forecasts with Strong Revenue and Profit Growth

Grifols reported a strong financial performance in the first quarter of 2025, exceeding forecasts with a 7.4% increase in revenues and a 14.2% rise in adjusted EBITDA. The company’s strategic execution and robust demand in the Biopharma sector contributed to a 179% growth in net profit and improved free cash flow by 209 million euros. Despite a temporary dip in albumin sales due to license renewal in China, Grifols maintained a solid liquidity position and reduced its leverage ratio, positioning itself for sustained growth in 2025.

The most recent analyst rating on (ES:GRF) stock is a Buy with a EUR22.00 price target. To see the full list of analyst forecasts on Grifols stock, see the ES:GRF Stock Forecast page.